| Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria A Lakshman, SV Rajkumar, FK Buadi, M Binder, MA Gertz, MQ Lacy, ... Blood cancer journal 8 (6), 59, 2018 | 268 | 2018 |
| Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma M Binder, SV Rajkumar, RP Ketterling, PT Greipp, A Dispenzieri, MQ Lacy, ... Blood cancer journal 7 (9), e600-e600, 2017 | 105 | 2017 |
| Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study … G Coltro, AA Mangaonkar, TL Lasho, CM Finke, P Pophali, R Carr, ... Leukemia 34 (5), 1407-1421, 2020 | 99 | 2020 |
| A simple additive staging system for newly diagnosed multiple myeloma NH Abdallah, M Binder, SV Rajkumar, PT Greipp, P Kapoor, A Dispenzieri, ... Blood cancer journal 12 (1), 21, 2022 | 83 | 2022 |
| RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis RM Carr, D Vorobyev, T Lasho, DL Marks, EJ Tolosa, A Vedder, ... Nature communications 12 (1), 2901, 2021 | 81 | 2021 |
| Mortality trends in multiple myeloma after the introduction of novel therapies in the United States M Binder, B Nandakumar, SV Rajkumar, P Kapoor, FK Buadi, D Dingli, ... Leukemia 36 (3), 801-808, 2022 | 74 | 2022 |
| Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients T Coston, P Pophali, R Vallapureddy, TL Lasho, CM Finke, RP Ketterling, ... American journal of hematology 94 (7), 767-779, 2019 | 69 | 2019 |
| Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis M Binder, M Uhl, T Wiech, F Kollert, J Thiel, JO Sass, UA Walker, ... Annals of the rheumatic diseases 71 (2), 311-312, 2012 | 66 | 2012 |
| Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms J Taylor, X Mi, K North, M Binder, A Penson, T Lasho, K Knorr, ... Blood, The Journal of the American Society of Hematology 136 (13), 1477-1486, 2020 | 56 | 2020 |
| Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia MM Patnaik, DA Sallman, AA Mangaonkar, R Heuer, J Hirvela, ... Blood, The Journal of the American Society of Hematology 136 (7), 909-913, 2020 | 55 | 2020 |
| Continued improvement in survival in multiple myeloma (MM) including high-risk patients. B Nandakumar, M Binder, A Dispenzieri, P Kapoor, F Buadi, MA Gertz, ... Journal of Clinical Oncology 37 (15_suppl), 8039-8039, 2019 | 53 | 2019 |
| Impact of HLA‐mismatch in unrelated donor hematopoietic stem cell transplantation: a meta‐analysis N Kekre, KS Mak, KH Stopsack, M Binder, K Ishii, E Brånvall, CS Cutler American Journal of Hematology 91 (6), 551-555, 2016 | 48 | 2016 |
| Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt … AA Mangaonkar, DM Swoboda, G Coltro, TL Lasho, PJ Novotny, ... Leukemia 34 (2), 656-661, 2020 | 47 | 2020 |
| Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study TG Cotter, M Binder, EV Loftus, R Abboud, MA McNally, TC Smyrk, ... Gut 67 (3), 441-446, 2018 | 43 | 2018 |
| Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation X You, F Liu, M Binder, A Vedder, T Lasho, Z Wen, X Gao, E Flietner, ... Blood, The Journal of the American Society of Hematology 139 (7), 1066-1079, 2022 | 42 | 2022 |
| Relative morphokinetics assessed by time-lapse imaging are altered in embryos from patients with endometriosis A Freis, JE Dietrich, M Binder, V Holschbach, T Strowitzki, A Germeyer Reproductive Sciences 25 (8), 1279-1285, 2018 | 40 | 2018 |
| Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma M Binder, SV Rajkumar, RP Ketterling, A Dispenzieri, MQ Lacy, MA Gertz, ... Blood cancer journal 6 (3), e401-e401, 2016 | 40 | 2016 |
| Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients M Li, M Binder, T Lasho, A Ferrer, N Gangat, A Al-Kali, A Mangaonkar, ... Blood Advances 5 (8), 2272-2278, 2021 | 38 | 2021 |
| Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia P Pophali, A Matin, AA Mangaonkar, R Carr, M Binder, A Al-Kali, ... Blood cancer journal 10 (11), 121, 2020 | 36 | 2020 |
| Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN … EC DiFilippo, G Coltro, RM Carr, AA Mangaonkar, M Binder, SP Khan, ... Leukemia 34 (9), 2519-2524, 2020 | 33 | 2020 |
